Business Context and Reporting Period
Company: CollPlant Biotechnologies Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: September 3, 2019
Context: The filing discloses the execution of Convertible Loan Agreements to raise capital for the Company's operations and intellectual property development.
Key Financial Metrics and Capital Structure
- Total Capital Raised: $6,500,000 (comprising two separate agreements).
- Tranche 1 (Ami Sagi): $3,000,000 total commitment; $2,000,000 received on September 3, 2019.
- Tranche 2 (U.S. Investors): $3,500,000 total commitment; expected closing by September 5, 2019.
- Interest Rate: 6% per annum, payable quarterly in arrears.
- Maturity: Three years from issuance.
- Conversion Price: $4.00 per American Depositary Share (ADS).
- Warrants Issued:
- Ami Sagi: Up to 750,000 ADSs (250,000 conditional on second closing; 500,000 on third closing).
- U.S. Investors: 875,000 ADSs.
Material Changes and Transaction Details
The Company entered into two distinct Convertible Loan Agreements on August 30, 2019, with closings occurring in September 2019:
- Ami Sagi Loan Agreement:
- First Closing: $2,000,000 received on September 3, 2019.
- Second Closing: $1,000,000 contingent upon execution of a license/co-development agreement with a strategic partner.
- Third Closing: Conversion of principal to ADSs and issuance of warrants contingent upon shareholder approval for Ami Sagi to hold voting rights exceeding 25%.
- U.S. Investors Loan Agreement:
- First Closing: $3,500,000 expected by September 5, 2019.
- Second Closing: Conversion of principal to ADSs and issuance of warrants contingent upon shareholder approval.
Anti-Dilution Provisions: Both agreements include "full-ratchet" price protection. If the Company issues equity below $4.00 per ADS within three years, the conversion price and warrant exercise price will adjust downward to the lower price, and additional ADSs may be issued.
Outlook, Risks, and Contingencies
- Contingent Closings: A portion of the capital ($1,000,000 from Ami Sagi) and the conversion of the entire loan principal are contingent upon specific milestones, including strategic partnership agreements and shareholder approval.
- Dilution Risk: The full-ratchet anti-dilution provisions and the issuance of warrants create significant potential dilution for existing shareholders if future equity is issued below $4.00 per ADS.
- Shareholder Approval: The transaction structure requires shareholder approval to allow Ami Sagi to exceed 25% voting rights and to trigger the conversion of loans into equity.
- Default Provisions: Loans become immediately due and payable upon certain events of default.
Investor Verification Checklist
- Verify the status of the $3,500,000 U.S. Investor tranche closing (expected by September 5, 2019).
- Confirm whether the Company has executed the strategic license/co-development agreement required to trigger the second tranche from Ami Sagi.
- Monitor the schedule and outcome of the required shareholder vote to approve Ami Sagi's increased voting rights and the loan conversions.
- Assess the impact of the "full-ratchet" anti-dilution clause on current and future share counts if the stock price trades below $4.00.
- Review the press release attached as Exhibit 99.1 for additional details on the use of proceeds.